image
Healthcare - Medical - Devices - NYSE - GB
$ 28.96
-0.069 %
$ 12.6 B
Market Cap
30.81
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one SNN stock under the worst case scenario is HIDDEN Compared to the current market price of 29 USD, Smith & Nephew plc is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one SNN stock under the base case scenario is HIDDEN Compared to the current market price of 29 USD, Smith & Nephew plc is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one SNN stock under the best case scenario is HIDDEN Compared to the current market price of 29 USD, Smith & Nephew plc is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
5.55 B REVENUE
6.40%
425 M OPERATING INCOME
34.92%
290 M NET INCOME
23.40%
608 M OPERATING CASH FLOW
29.91%
-448 M INVESTING CASH FLOW
5.08%
-200 M FINANCING CASH FLOW
78.40%
2.83 B REVENUE
0.43%
328 M OPERATING INCOME
-19.41%
214 M NET INCOME
135.16%
238 M OPERATING CASH FLOW
-51.92%
-360 M INVESTING CASH FLOW
-35.34%
372 M FINANCING CASH FLOW
426.32%
Balance Sheet Smith & Nephew plc
image
Current Assets 4.03 B
Cash & Short-Term Investments 302 M
Receivables 1.06 B
Other Current Assets 2.67 B
Non-Current Assets 5.96 B
Long-Term Investments 24 M
PP&E 1.47 B
Other Non-Current Assets 4.46 B
Current Liabilities 2.27 B
Accounts Payable 1.02 B
Short-Term Debt 765 M
Other Current Liabilities 490 M
Non-Current Liabilities 2.5 B
Long-Term Debt 2.32 B
Other Non-Current Liabilities 180 M
EFFICIENCY
Earnings Waterfall Smith & Nephew plc
image
Revenue 5.55 B
Cost Of Revenue 1.73 B
Gross Profit 3.82 B
Operating Expenses 3.47 B
Operating Income 425 M
Other Expenses 135 M
Net Income 290 M
RATIOS
70.14% GROSS MARGIN
70.14%
7.66% OPERATING MARGIN
7.66%
4.74% NET MARGIN
4.74%
5.04% ROE
5.04%
2.63% ROA
2.63%
4.54% ROIC
4.54%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Smith & Nephew plc
image
Net Income 290 M
Depreciation & Amortization 527 M
Capital Expenditures -427 M
Stock-Based Compensation 39 M
Change in Working Capital -332 M
Others -21 M
Free Cash Flow 181 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Smith & Nephew plc
image
Wall Street analysts predict an average 1-year price target for SNN of $27 , with forecasts ranging from a low of $27 to a high of $27 .
SNN Lowest Price Target Wall Street Target
27 USD -6.77%
SNN Average Price Target Wall Street Target
27 USD -6.77%
SNN Highest Price Target Wall Street Target
27 USD -6.77%
4. DIVIDEND ANALYSIS
0.93% DIVIDEND YIELD
0.288 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Smith & Nephew plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Smith & Nephew has to impress in results after ringing warning bell Smith & Nephew PLC has left itself with the mounting task of having to give investors something to cheer about after ringing the warning bell last time out. Ahead of full-year figures on Tuesday, 25 February, AJ Bell analysts noted the medical equipment maker flagged it and chief executive Deepak Nath needed to reassure. proactiveinvestors.co.uk - 1 week ago
Smith+Nephew steps forward with innovative Sports Medicine foot & ankle repair solutions in Australia and New Zealand First in market to o ffe r A djustable T ensioning T echnology * for i nsertional A chilles r econstruction and l ateral a nkle i nstability r epair globenewswire.com - 2 weeks ago
Smith+Nephew and UFC to host first-of-its-kind medical education course for treatment of injuries in combat sport athletes Healthcare professionals are invited to register for the livestream option as a courtesy  here globenewswire.com - 4 weeks ago
Smith & Nephew Getting No Credit For Self-Improvement Efforts Smith & Nephew's stock has underperformed, driven by ongoing market share losses in hip and knee markets and pricing pressures in China, raising concerns about its ongoing multiyear restructuring program. The upcoming fourth quarter results may not significantly help, given ongoing market share pressure in major joints, ongoing headwinds in China, and a lack of clear growth engines. Smith & Nephew needs to execute its self-improvement plan effectively to close the value gap and regain investor confidence in its turnaround strategy, particularly in the major joint business. seekingalpha.com - 1 month ago
Smith+Nephew's ALLEVYN™ LIFE Sacrum Foam Dressing and LEAF™ Patient Monitoring System receive ‘favorable' Evidence Bar™ ratings from ECRI for pressure injury prevention Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that ECRI – leaders in advancing evidence-based healthcare globally - have completed updated Clinical Evidence Assessments of ALLEVYN LIFE Sacrum Foam Dressings and the LEAF Patient Monitoring System. In their latest reports, ECRI upgraded its Evidence Bar ratings for both to favorable* after assessing the most recently published clinical evidence and key outcomes for pressure injury prevention. globenewswire.com - 1 month ago
Topical Scar Treatment Market to Grow from $1.71 Billion in 2024 to $5.91 Billion by 2035 - Dominated by Smith & Nephew, Molnlycke Health Care, Alliance Pharma, HRA Pharma, and Rejuvaskin Scar Treatment Market Booms with Rising Skin-Related Surgeries and Burn Cases Globally Scar Treatment Market Booms with Rising Skin-Related Surgeries and Burn Cases Globally globenewswire.com - 1 month ago
SNN Stock May Gain on CORIOGRAPH Platform's FDA Clearance for THA Smith & Nephew announces FDA clearance for its CORIOGRAPH platform for total hip arthroplasty. zacks.com - 2 months ago
Smith+Nephew introduces CORIOGRAPH™ Pre-Op Planning and Modeling Services for Total Hip Arthroplasty Latest expansion to the CORI◊ Surgical System portfolio provides a personalized solution for patients and surgeons Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces its CORIOGRAPH Pre-Op Planning and Modeling Services is now cleared for total hip arthroplasty (THA) by the United States Food and Drug Administration. Exclusively for users of the CORI Surgical System, this innovative planning software allows for use of either X-rays or CT scans for planning and modeling, enabling surgeons to make a patient-specific plan for the best possible outcome. globenewswire.com - 2 months ago
SNN Stock Might Rise Following FDA Nod for AETOS Stemless Smith & Nephew received FDA 510(k) clearance for a stemless anatomic total shoulder, AETOS Stemless. This represents a significant advancement in shoulder arthroplasty. zacks.com - 2 months ago
Smith+Nephew expands AETOS™ Shoulder System with new stemless option for anatomic shoulder arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance from the United States Food & Drug Administration for a stemless anatomic total shoulder for the AETOS Shoulder System (AETOS Stemless). globenewswire.com - 2 months ago
Smith & Nephew has the potential to pop next year, says leading US investment bank JP Morgan has doubled down on its "overweight" recommendation for Smith & Nephew PLC (LSE:SN) with its analysts deeming the medical device company undervalued, trading near trough levels, with potential for significant re-rating. Despite challenges in the broader European medtech sector, S&N stands out as a value pick with promising recovery prospects. proactiveinvestors.co.uk - 2 months ago
Big investors call for break-up of Smith & Nephew, FT reports Three major investors are pushing medical device maker Smith & Nephew to consider a break-up of the business, the Financial Times reported on Thursday, citing shareholders. reuters.com - 3 months ago
8. Profile Summary

Smith & Nephew plc SNN

image
COUNTRY GB
INDUSTRY Medical - Devices
MARKET CAP $ 12.6 B
Dividend Yield 0.93%
Description Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Contact Building 5, Watford, WD18 8YE https://www.smith-nephew.com
IPO Date Nov. 16, 1999
Employees 18000
Officers Ms. Helen Barraclough Group General Counsel & Company Secretary Ms. Elga Lohler Chief Human Resources Officer Mr. Philip G. Cowdy Chief Corporate Development & Corporate Affairs Officer Dr. Vasant Padmanabhan Ph.D. President of Research & Development and Ear, Nose & Throat Mr. Paul Connolly President of Global Operations Mr. John Terence Rogers Chief Financial Officer & Executive Director Ms. Alison Parkes Chief Compliance Officer & Compliance APAC Dr. Deepak S. Nath Ph.D. Chief Executive Officer & Director Mr. Andrew Swift Vice President of Investor Relations Mr. Joe Metzger Senior Vice President of Marketing Services & Communications